RAJAF · OTC · CIK 0001885680

TFA Therapeutics, Inc.

TFA Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form 6-K filed on Sep 2, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $1.2M and net income of -$154.8K, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$1.2M
Net income, FY2025
-$154.8K
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
TFA Therapeutics, Inc.
Ticker
RAJAF
SEC Central Index Key (CIK)
0001885680
Business address
TAIPEI CITY
State or country of incorporation
—
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Emerging growth company
Position in SEC ticker list
#2420 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from TFA Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$879.3KFY2021$53.3KFY2022$882.5KFY2023$1.3MFY2024$1.2MFY2025
Net income
-$491.0KFY2021-$720.1KFY2022$751.6KFY2023-$226.3KFY2024-$154.8KFY2025
RAJAF annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$879.3K$53.3K$882.5K$1.3M$1.2M
Net income-$491.0K-$720.1K$751.6K-$226.3K-$154.8K
Diluted EPS-$4.91-$0.01$0.01$0.00$0.00
Total assets$3.3M$2.1M$3.4M$4.6M$4.7M
Cash and equivalents$99.7K$6.6K$23.1K$37.3K$3.2K

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

RAJAF latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
May 15, 202620-FANNUAL REPORT· period Dec 31, 2025Document · Index
Sep 2, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Sep 2, 2026Document · Index

Recent SEC filings

The 38 newest documents filed by or about TFA Therapeutics, Inc., by form type:

6-K ×8UPLOAD ×620-F ×4NT 20-F ×4CORRESP ×420-F/A ×2F-1/A ×2DRSLTR ×2DRS/A ×2424B4 ×1EFFECT ×1F-1 ×1DRS ×1
RAJAF recent filings
FiledFormWhat it isOriginal
Sep 2, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Sep 2, 2026Document · Index
Jul 27, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jul 27, 2026Document · Index
Jun 25, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 25, 2026Document · Index
May 15, 202620-FANNUAL REPORT· period Dec 31, 2025Document · Index
Apr 30, 2026NT 20-FNOTIFICATION OF LATE FILING· period Dec 31, 2025Document · Index
Nov 26, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Nov 25, 2025Document · Index
Sep 23, 202520-F/AAMENDMENT NO. 2 TO FORM 20-F· period Dec 31, 2023Document · Index
Jun 13, 202520-FANNUAL REPORT· period Dec 31, 2024Document · Index
Apr 30, 2025NT 20-FNOTIFICATION OF LATE FILING· period Dec 31, 2024Document · Index
Dec 6, 20246-KREPORT OF FOREIGN PRIVATE ISSUER· period Dec 6, 2024Document · Index
Nov 8, 2024UPLOADUPLOADDocument · Index
Oct 28, 2024CORRESPCORRESPDocument · Index
Oct 28, 202420-F/AAMENDMENT NO. 1 TO FORM 20-F· period Dec 31, 2023Document · Index
Sep 4, 2024UPLOADUPLOADDocument · Index
Jul 5, 202420-FANNUAL REPORT· period Dec 31, 2023Document · Index
Apr 30, 2024NT 20-FNOTIFICATION OF LATE FILING· period Dec 31, 2023Document · Index
Mar 19, 20246-KREPORT OF FOREIGN PRIVATE ISSUER· period Mar 18, 2024Document · Index
Nov 13, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Sep 30, 2023Document · Index
Sep 28, 20236-KCURRENT REPORT· period Sep 28, 2023Document · Index
May 15, 202320-FANNUAL REPORT· period Dec 31, 2022Document · Index
Apr 28, 2023NT 20-FEXTENSION FORM· period Dec 31, 2022Document · Index
Mar 30, 2023424B4PROSPECTUSDocument · Index
Mar 29, 2023EFFECTEFFECTDocument · Index
Mar 27, 2023CORRESPCORRESPDocument · Index
Mar 20, 2023CORRESPCORRESPDocument · Index
Mar 20, 2023F-1/AREGISTRATION STATEMENTDocument · Index
Mar 17, 2023UPLOADUPLOADDocument · Index
Mar 6, 2023F-1/AREGISTRATION STATEMENTDocument · Index
Jan 20, 2023CORRESPCORRESPDocument · Index
Jan 20, 2023F-1REGISTRATION STATEMENTDocument · Index
Dec 21, 2022UPLOADUPLOADDocument · Index
Dec 8, 2022DRSLTRDRSLTRDocument · Index
Dec 8, 2022DRS/ADRS/ADocument · Index
Oct 19, 2022UPLOADUPLOADDocument · Index
Sep 20, 2022DRSLTRDRSLTRDocument · Index
Sep 20, 2022DRS/ADRS/ADocument · Index
Jan 11, 2022UPLOADUPLOADDocument · Index
Dec 6, 2021DRSDRSDocument · Index

Insider filing activity

0 Form 4 filings appear in TFA Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Medicinal Chemicals & Botanical Products

All 6 companies in Medicinal Chemicals & Botanical Products

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001885680 and XBRL company facts. TFA Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.